ClinicalTrials.gg
CompletedNCT06385561Updated Apr 26, 2024

The Influence of Tramadol on Opioid-induced Bowel Dysfunction

A Phase 2 interventional study of Tramadol and Placebo in Opioid-Induced Bowel Dysfunction and Constipation, sponsored by Asbjørn Mohr Drewes. Completed at 1 site in Denmark. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-26.

Sponsored by Asbjørn Mohr Drewes · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Aug 2022, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

Tramadol is a weak opioid and widely used to treat moderate to severe pain. Stronger opioids are known to inhibit gastrointestinal motility and secretion, however the effects of tramadol on gastrointestinal function remains less understood. The aim of this study was to determine to what degree tramadol causes opioid-induced bowel dysfunction by using an objective design to explore gastrointestinal transit, motility pattern, secretion, and colonic volume, in a group of healthy male volunteers.

02

Conditions studied

  • Opioid-Induced Bowel Dysfunction
  • Constipation
03

In context

Opioid-Induced Constipation

87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.

This study's enrollment of 20 is below the median of 119 across 68 interventional studies indexed under Opioid-Induced Constipation.

Browse Opioid-Induced Constipation studies →

Lead sponsor

Asbjørn Mohr Drewes is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy (assessed by a study-affiliated medical doctor.)
  • Signed .
  • Able to read and understand Danish.
  • Male (to avoid influence of menstrual cycles)
  • Northern European descent (to minimize genetic variance influences on drug metabolism).
  • The researcher believes that the participant understands the study details, is compliant and is expected to complete the study.
  • Opioid naïve* (who have not taken prescription opioid for one week or longer and at least a year have passed since completion of a previous opioid study.)
  • Between 20 and 40 years of age.
  • A State Trait Anxiety Inventory (STAI) score in the range of 20-37 i.e., classified as "no or low anxiety" at inclusion.

Exclusion criteria

Exclusion Criteria:

  • Known or allergy towards the used pharmaceutical compounds or pharmaceutical compounds similar to those used in the study.
  • Less than three spontaneous bowel movements per week.
  • Participation in other studies within 14 days prior to first visit.
  • Expected need of medical/surgical treatment during the study.
  • Any diagnosed disease, which investigator concludes will affect the trial (including all complications: severe , pulmonary heart disease, severe bronchial asthma, paralytic ileus, hypercapnia, serious respiratory depression with hypoxia, moderate to severe decreased liver function, gastrointestinal obstruction or perforation, acute surgical abdominal complications such as appendicitis, Mb. Crohn's, ulcerative colitis, and toxic mega colon).
  • History of substance abuse (alcohol, tetrahydrocannabinol (THC), benzodiazepine, central stimulants and/or opioids, urine drug test will be performed prior to treatment start). ¹
  • History of major mental disorders (e.g., major anxiety, major depression or treatment with psychoactive medications etc.) ²
  • Metal implants or pacemaker.
  • Daily use of prescription only medicine
  • Daily alcohol consumption
  • Participation motivated by "wrongful" reasons such as poor economy, or psychosocial issues e.g., problems in the family, loneliness, sadness. People with such problems may be more likely to develop substance dependence.1
  • Intake of alcohol within 48 hours before start of study period or any alcohol consumption during each study period. If consumption takes place during the study the participant will be excluded.
  • Use of any analgesic medication within 48 hours before start as well as for the duration of the study. If consumption takes place during the study the participant will be excluded.
  • Nicotine use
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Active treatment

    Tramadol

    Drug: Tramadol

  • Placebo comparator
    Placebo treatment

    Placebo

    Drug: Placebo

Interventions

  • Tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200 mg)

  • DrugPlacebo

    Placebo is administered orally twice daily.

06

What researchers measure

Primary outcomes

  1. Total gastrointestinal transit time

    Difference in hours from ingestion of a 3D Transit Capsule to expulsion of the capsule during active and placebo treatment

    Time frame: From day 4 to day 8

  2. Colorectal transit time

    Difference in hours from the entering in the colon of a 3D Transit Capsule to expulsion of the capsule during active and placebo treatment

    Time frame: From day 4 to day 8

Secondary outcomes

  1. Constipation symptoms

    Measured on the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire (ranging from 0 (symptom absent) to 4 (very severe).

    Time frame: From day 1 to day 10

  2. Bowel movement frequency

    Number of spontaneous bowel movements per day

    Time frame: From day 1 to day 10

  3. Stool consistency

    Rated on the Bristol Stool Form Scale (ranging from type 1 (constipation) - type 7 (diarrhea))

    Time frame: From day 1 to day 10

  4. Gastrointestinal symptoms

    Measured on the Gastrointestinal Symptom Rating Score (GSRS) questionnaire (ranging from 0 (no discomfort) to 6 (very severe discomfort)

    Time frame: Day 1 and day 10

  5. Opioid-induced constipation

    Measured by the Bowel Function Index (BFI) questionnaire (ranging from 0 (not at all) to 100 (very strong).

    Time frame: Day 1 and day 10

  6. Diagnostic evaluation of opioid-induced constipation

    Assessed using the Rome IV C6 criteria consisting of 7 items rated as either true or false. 2 or more items rated as "true" indicates functional constipation

    Time frame: Day 10

  7. Colonic motility patterns

    Number of motility patterns in the colon measured by the 3D Transit Capsule

    Time frame: From day 4 to day 8

  8. Opiate withdrawal symptoms

    Measured by the Subjective Opiate Withdrawal Scale (ranging from 0 (not at all) to 4 /extremely)

    Time frame: Day 13, 14 or 15

  9. Colon volume

    Volumetric quantification of the colon measured using T2-weighted MRI images

    Time frame: Day 10

  10. Colonic water content

    Analysis of colonic water content measured using heavily T2-weighted MRI images

    Time frame: Day 10

  11. Gastric half emptying time

    Analysis of gastric half emptying time after ingestion of a standardized meal measured by MRI

    Time frame: Day 1 and day 10

  12. Gastric contraction assessment

    Analysis of gastric contraction amplitude after ingestion of a standardized meal measured by MRI

    Time frame: Day 1 and day 10

  13. Gastric contraction assessment

    Analysis of gastric contraction frequency after ingestion of a standardized meal measured by MRI

    Time frame: Day 1 and day 10

  14. Small bowel motility assessment

    Analysis of small bowel motility after ingestion of a standardized meal measured using dynamic MRI images. A semi-automated analysis software enables registration of small bowel motility with the calculation of regional motility maps and quantification of motility indices.

    Time frame: Day 1 and day 10

  15. Small bowel water content

    Analysis of small bowel water content measured using heavily T2-weighted MRI images

    Time frame: Day 1 and day 10

07

Study locations

1 site
  • Aalborg University Hospital
    Aalborg, 9000, Denmark
08

References and documents

Individual participant data

Plan to share: Yes — Data can be provided upon request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in May 2023, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2024
First posted
Apr 26, 2024
StartActual
Aug 11, 2022
Primary completionActual
May 15, 2023
CompletionActual
May 15, 2023
Last update
Apr 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06385561
Lead sponsor
Asbjørn Mohr Drewes
Responsible party
Asbjørn Mohr Drewes (Professor, Aalborg University Hospital) — Sponsor-investigator
First posted
Apr 26, 2024
Start date
Aug 11, 2022
Primary completion
May 15, 2023
Completion
May 15, 2023
Last update
Apr 26, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tramadol

Start the discussion